24/7 Market News Snapshot 06 October, 2025 – Gain Therapeutics, Inc. Common Stock (NASDAQ:GANX)

October 6, 2025

DENVER, Colo., 06 October, 2025 (www.247marketnews.com) – (NASDAQ:GANX) are discussed in this article.
Gain Therapeutics, Inc. (NASDAQ:GANX), a forward-thinking clinical-stage biotechnology company focused on innovative allosteric therapies, has recently caught significant market attention with a notable stock surge. Opening at $1.955 and soaring to $2.305, the stock marked an impressive gain of over 20% from its previous close of $1.920, signaling robust investor confidence and interest in the company’s advancements.

The upward momentum is particularly fueled by promising interim results from the ongoing Phase 1b clinical study of GT-02287, a potential treatment for Parkinson’s disease (PD). These findings, presented at the International Congress of Parkinson’s Disease and Movement Disorders®, showcased significant improvements in MDS-UPDRS scores among the first nine participants after just 90 days of treatment. Many participants exhibited enhanced scores in functional aspects of PD, suggesting GT-02287’s viability as a disease-modifying agent.

Importantly, the treatment has demonstrated a favorable safety profile, with no serious adverse events reported thus far, following evaluations from independent data monitoring committees. Gene Mack, President and Chief Executive Officer of Gain Therapeutics, commented on the stability and positive trends observed, emphasizing the treatment’s potential impact on PD progression.

The ongoing study, which includes 21 participants currently receiving treatment, is notable for its flexibility, allowing patients on various PD therapies to participate. Additionally, recent approvals grant participants the opportunity for treatment extensions up to 12 months, reinforcing the company’s dedication to advancing research in neurodegenerative diseases.

In light of these developments, Gain Therapeutics will hold a virtual Key Opinion Leader (KOL) event on October 14, 2025, at 4:00 PM ET, where further details about the clinical findings will be shared, aiming to provide deeper insights into the exciting potential of GT-02287. As the company paves the way in advancing innovative treatments, the financial and therapeutic landscapes stand poised for notable transformation.

Related news for (GANX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.